STOCK TITAN

RTW Investments swaps Allurion (ALUR) stock into pre-funded warrants

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

RTW Investments, LP and affiliated funds restructured holdings in Allurion Technologies on July 21, 2026 by exchanging 209,254, 161,807, 19,934 and 1,771 shares of Common Stock for equal numbers of Pre-Funded Warrants exercisable at $0.0001 per share. The warrants are exercisable immediately, have no expiration, and are subject to a 9.99% beneficial ownership cap; share counts reflect a 1-for-15 reverse stock split completed June 18, 2026.

Positive

  • None.

Negative

  • None.
Insider RTW INVESTMENTS, LP, WONG RODERICK
Role 10% Owner | 10% Owner
Type Security Shares Price Value
Other Pre-Funded Warrant (Right to Buy) F1, F10, F2, F3 209,254 -- --
Other Pre-Funded Warrant (Right to Buy) F4, F10, F2, F5 161,807 -- --
Other Pre-Funded Warrant (Right to Buy) F6, F10, F2, F7 19,934 -- --
Other Pre-Funded Warrant (Right to Buy) F8, F10, F2, F9 1,771 -- --
Other Common Stock, $0.0001 par value per share F1, F2, F3 209,254 -- --
Other Common Stock, $0.0001 par value per share F4, F2, F5 161,807 -- --
Other Common Stock, $0.0001 par value per share F6, F2, F7 19,934 -- --
Other Common Stock, $0.0001 par value per share F8, F2, F9 1,771 -- --
Holdings After Transaction: Pre-Funded Warrant (Right to Buy) — 392,766 shares (Indirect, See Footnotes); Common Stock, $0.0001 par value per share — 0 shares (Indirect, See footnotes)
Footnotes (10)
  1. F1. On July 21, 2026, RTW Master Fund, Ltd. ("Master Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a "Pre-Funded Warrant").
  2. F2. RTW Investments, LP (the "Adviser") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. ("RTW Innovation"), RTW Biotech Opportunities Operating Ltd. ("RTW Biotech Fund") and other funds or accounts managed by the Adviser (each, an "Other RTW Fund"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. F3. Held directly by Master Fund.
  4. F4. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 161,807 shares of the Issuer's Common Stock.
  5. F5. Held directly by RTW Innovation.
  6. F6. On July 21, 2026, RTW Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of the Issuer's Common Stock.
  7. F7. Held directly by RTW Biotech Fund.
  8. F8. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock.
  9. F9. Held by an Other RTW Fund.
  10. F10. The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
Shares exchanged by Master Fund 209,254 shares Exchanged for a Pre-Funded Warrant on July 21, 2026
Shares exchanged by RTW Innovation 161,807 shares Exchanged for a Pre-Funded Warrant on July 21, 2026
Shares exchanged by RTW Biotech Fund 19,934 shares Exchanged for a Pre-Funded Warrant on July 21, 2026
Shares exchanged by Other RTW Fund 1,771 shares Exchanged for a Pre-Funded Warrant on July 21, 2026
Pre-Funded Warrant exercise price $0.0001 per share Exercise price of each Pre-Funded Warrant received in the exchanges
Beneficial ownership cap 9.99% Maximum aggregate beneficial ownership after warrant exercise including Attribution Parties
Reverse stock split ratio 1-for-15 Allurion reverse stock split effected June 18, 2026; share counts are post-split
Pre-Funded Warrant financial
"exchanged shares of Common Stock for a pre-funded warrant exercisable for up to those shares"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
Exchange Agreement financial
"entered into an Exchange Agreement with the issuer pursuant to which shares were exchanged"
A written deal in which two parties agree to swap assets, securities or obligations under set terms—think of it as a formal swap or trade contract. For investors it matters because such agreements can change who owns what, alter a company’s capital structure, affect future cash flows or dilute existing shares, and therefore influence value and risk in a straightforward, contract-driven way.
beneficial ownership regulatory
"cause the aggregate number of shares of Common Stock beneficially owned by the holder"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Attribution Parties regulatory
"together with its Attribution Parties as defined in the Pre-Funded Warrant"
reverse stock split financial
"effected a 1-for-15 reverse stock split; the share counts herein reflect it"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What transactions did RTW Investments report in Allurion Technologies (ALUR) on this Form 4?

RTW Investments and affiliated funds exchanged existing Common Stock of Allurion Technologies for Pre-Funded Warrants. The exchanges occurred on July 21, 2026 and involved several RTW-managed funds, with each fund swapping its shares for a warrant over the same number of shares.

How many Allurion (ALUR) shares were exchanged for Pre-Funded Warrants?

RTW-managed funds exchanged 209,254, 161,807, 19,934 and 1,771 shares of Allurion Common Stock. Each block of shares was swapped for a Pre-Funded Warrant exercisable for an equal number of shares, for no additional consideration under Exchange Agreements with the company.

What are the key terms of the Allurion (ALUR) Pre-Funded Warrants received by RTW funds?

Each Pre-Funded Warrant is exercisable immediately at an exercise price of $0.0001 per share. The warrants have no expiration date and include a 9.99% beneficial ownership cap that limits exercises based on the holder’s aggregate ownership with its related parties.

How does the 9.99% beneficial ownership cap affect ALUR warrant exercises?

The Pre-Funded Warrants cannot be exercised if doing so would cause the holder, together with its Attribution Parties, to own more than 9.99% of Allurion’s outstanding Common Stock. This cap limits how many shares can be issued on exercise at any given time.

What is the impact of the 1-for-15 reverse stock split on ALUR share counts in this Form 4?

Allurion completed a 1-for-15 reverse stock split on June 18, 2026. The reported share amounts for both Common Stock and Pre-Funded Warrants already reflect this adjustment, so the numbers shown are on a post-split basis for all transactions disclosed.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, 7TH FLOOR

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ALLURION TECHNOLOGIES, INC. [ ALUR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, $0.0001 par value per share07/21/2026J(1)209,254D(1)0ISee footnotes(2)(3)
Common Stock, $0.0001 par value per share07/21/2026J(4)161,807D(4)0ISee footnotes(2)(5)
Common Stock, $0.0001 par value per share07/21/2026J(6)19,934D(6)0ISee footnotes(2)(7)
Common Stock, $0.0001 par value per share07/21/2026J(8)1,771D(8)0ISee footnotes(2)(9)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Pre-Funded Warrant (Right to Buy)$0.000107/21/2026J(1)209,254 (10) (10)Common Stock209,254(1)209,254ISee Footnotes(2)(3)
Pre-Funded Warrant (Right to Buy)$0.000107/21/2026J(4)161,807 (10) (10)Common Stock161,807(4)161,807ISee footnotes(2)(5)
Pre-Funded Warrant (Right to Buy)$0.000107/21/2026J(6)19,934 (10) (10)Common Stock19,934(6)19,934ISee footnotes(2)(7)
Pre-Funded Warrant (Right to Buy)$0.000107/21/2026J(8)1,771 (10) (10)Common Stock1,771(8)1,771ISee footnotes(2)(9)
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, 7TH FLOOR

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
WONG RODERICK

(Last)(First)(Middle)
40 10TH AVENUE, 7TH FLOOR

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. On July 21, 2026, RTW Master Fund, Ltd. ("Master Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a "Pre-Funded Warrant").
2. RTW Investments, LP (the "Adviser") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. ("RTW Innovation"), RTW Biotech Opportunities Operating Ltd. ("RTW Biotech Fund") and other funds or accounts managed by the Adviser (each, an "Other RTW Fund"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
3. Held directly by Master Fund.
4. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 161,807 shares of the Issuer's Common Stock.
5. Held directly by RTW Innovation.
6. On July 21, 2026, RTW Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of the Issuer's Common Stock.
7. Held directly by RTW Biotech Fund.
8. On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock.
9. Held by an Other RTW Fund.
10. The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
Remarks:
On June 18, 2026, the Issuer effected a 1-for-15 reverse stock split. The share counts herein reflect the reverse stock split.
/s/ Roderick Wong, M.D. - For RTW Investments, L.P., By: Roderick Wong, M.D., Managing Partner07/23/2026
/s/ Roderick Wong, M.D.07/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)